blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3746451

EP3746451 - BENZYL-, (PYRIDIN-3-YL)METHYL- OR (PYRIDIN-4-YL)METHYL-SUBSTITUTED OXADIAZOLOPYRIDINE DERIVATIVES AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  17.05.2024
Database last updated on 03.09.2024
FormerThe patent has been granted
Status updated on  09.06.2023
FormerGrant of patent is intended
Status updated on  06.02.2023
FormerExamination is in progress
Status updated on  18.02.2022
FormerRequest for examination was made
Status updated on  07.02.2022
FormerGrant of patent is intended
Status updated on  04.11.2021
FormerRequest for examination was made
Status updated on  18.10.2021
FormerGrant of patent is intended
Status updated on  04.07.2021
FormerRequest for examination was made
Status updated on  06.11.2020
FormerThe international publication has been made
Status updated on  10.08.2019
Formerunknown
Status updated on  11.02.2019
Most recent event   Tooltip30.08.2024Lapse of the patent in a contracting state
New state(s): MC		published on 02.10.2024 [2024/40]
Applicant(s)For all designated states
Boehringer Ingelheim International GmbH
Binger Strasse 173
55216 Ingelheim am Rhein / DE
[2020/50]
Inventor(s)01 / TRIESELMANN, Thomas
Boehringer Ingelheim International GmbH
Corporate Patents
Binger Strasse 173
55216 Ingelheim am Rhein / DE
02 / GODBOUT, Cédrickx
Boehringer Ingelheim International GmbH
Corporate Patents
Binger Strasse 173
55216 Ingelheim am Rhein / DE
03 / HOENKE, Christoph
Boehringer Ingelheim International GmbH
Corporate Patents
Binger Strasse 173
55216 Ingelheim am Rhein / DE
04 / VINTONYAK, Viktor
Boehringer Ingelheim International GmbH
Corporate Patents
Binger Strasse 173
55216 Ingelheim am Rhein / DE
 [2020/50]
Representative(s)Lutze, Oliver, et al
Boehringer Ingelheim International GmbH
Binger Straße 173
55216 Ingelheim am Rhein / DE
[N/P]
Former [2020/50]Simon, Elke Anna Maria, et al
Boehringer Ingelheim GmbH
Binger Strasse 173
55216 Ingelheim am Rhein / DE
Application number, filing date19702246.028.01.2019
[2020/50]
WO2019EP51989
Priority number, dateEP2018015482402.02.2018         Original published format: EP 18154824
[2020/50]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2019149657
Date:08.08.2019
Language:EN
[2019/32]
Type: A1 Application with search report 
No.:EP3746451
Date:09.12.2020
Language:EN
The application published by WIPO in one of the EPO official languages on 08.08.2019 takes the place of the publication of the European patent application.
[2020/50]
Type: B1 Patent specification 
No.:EP3746451
Date:12.07.2023
Language:EN
[2023/28]
Search report(s)International search report - published on:EP08.08.2019
ClassificationIPC:C07D498/04, C07D519/00, A61P3/00, A61P3/10, A61K31/437, A61K31/444, A61K31/5377, A61K31/497, A61K31/501, A61K31/4545
[2020/50]
CPC:
C07D498/04 (EP,IL,KR,US); A61K31/437 (KR); A61K31/444 (KR);
A61P3/00 (EP,IL); A61P3/04 (KR); A61P3/10 (EP,IL,KR);
C07D519/00 (EP,IL,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/50]
Extension statesBA02.09.2020
ME02.09.2020
Validation statesMA02.09.2020
TN02.09.2020
TitleGerman:BENZYL-, (PYRIDIN-3-YL)METHYL- ODER (PYRIDIN-4-YL)METHYL-SUBSTITUIERTE OXADIAZOLOPYRIDINDERIVATE ALS INHIBITOREN DER GHRELIN-O-ACYL-TRANSFERASE (GOAT)[2020/50]
English:BENZYL-, (PYRIDIN-3-YL)METHYL- OR (PYRIDIN-4-YL)METHYL-SUBSTITUTED OXADIAZOLOPYRIDINE DERIVATIVES AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS[2020/50]
French:DÉRIVÉS D'OXADIAZOLOPYRIDINE À SUBSTITUTION BENZYLE, (PYRIDIN-3-YL)MÉTHYLE OU (PYRIDIN-4-YL)MÉTHYLE UTILISÉS EN TANT QU'INHIBITEURS DE LA GHRÉLINE O-ACYLTRANSFÉRASE (GOAT)[2020/50]
Entry into regional phase02.09.2020National basic fee paid 
02.09.2020Designation fee(s) paid 
02.09.2020Examination fee paid 
Examination procedure14.08.2020Amendment by applicant (claims and/or description)
02.09.2020Examination requested  [2020/50]
02.09.2020Date on which the examining division has become responsible
05.07.2021Communication of intention to grant the patent
15.10.2021Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
05.11.2021Communication of intention to grant the patent
07.02.2022Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
17.02.2022Despatch of a communication from the examining division (Time limit: M02)
25.03.2022Reply to a communication from the examining division
07.02.2023Communication of intention to grant the patent
31.05.2023Fee for grant paid
31.05.2023Fee for publishing/printing paid
31.05.2023Receipt of the translation of the claim(s)
Opposition(s)15.04.2024No opposition filed within time limit [2024/25]
Fees paidRenewal fee
01.02.2021Renewal fee patent year 03
31.01.2022Renewal fee patent year 04
31.01.2023Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT12.07.2023
CZ12.07.2023
DK12.07.2023
EE12.07.2023
ES12.07.2023
FI12.07.2023
HR12.07.2023
IT12.07.2023
LT12.07.2023
LV12.07.2023
MC12.07.2023
NL12.07.2023
PL12.07.2023
RO12.07.2023
RS12.07.2023
SE12.07.2023
SI12.07.2023
SK12.07.2023
SM12.07.2023
NO12.10.2023
GR13.10.2023
IS12.11.2023
PT13.11.2023
[2024/40]
Former [2024/36]AT12.07.2023
CZ12.07.2023
DK12.07.2023
EE12.07.2023
ES12.07.2023
FI12.07.2023
HR12.07.2023
IT12.07.2023
LT12.07.2023
LV12.07.2023
NL12.07.2023
PL12.07.2023
RO12.07.2023
RS12.07.2023
SE12.07.2023
SI12.07.2023
SK12.07.2023
SM12.07.2023
NO12.10.2023
GR13.10.2023
IS12.11.2023
PT13.11.2023
Former [2024/26]AT12.07.2023
CZ12.07.2023
DK12.07.2023
EE12.07.2023
ES12.07.2023
FI12.07.2023
HR12.07.2023
IT12.07.2023
LT12.07.2023
LV12.07.2023
NL12.07.2023
PL12.07.2023
RO12.07.2023
RS12.07.2023
SE12.07.2023
SK12.07.2023
SM12.07.2023
NO12.10.2023
GR13.10.2023
IS12.11.2023
PT13.11.2023
Former [2024/23]AT12.07.2023
CZ12.07.2023
DK12.07.2023
EE12.07.2023
ES12.07.2023
FI12.07.2023
HR12.07.2023
LT12.07.2023
LV12.07.2023
NL12.07.2023
PL12.07.2023
RO12.07.2023
RS12.07.2023
SE12.07.2023
SK12.07.2023
SM12.07.2023
NO12.10.2023
GR13.10.2023
IS12.11.2023
PT13.11.2023
Former [2024/22]AT12.07.2023
CZ12.07.2023
DK12.07.2023
ES12.07.2023
FI12.07.2023
HR12.07.2023
LT12.07.2023
LV12.07.2023
NL12.07.2023
PL12.07.2023
RO12.07.2023
RS12.07.2023
SE12.07.2023
SM12.07.2023
NO12.10.2023
GR13.10.2023
IS12.11.2023
PT13.11.2023
Former [2024/20]AT12.07.2023
ES12.07.2023
FI12.07.2023
HR12.07.2023
LT12.07.2023
LV12.07.2023
NL12.07.2023
PL12.07.2023
RS12.07.2023
SE12.07.2023
SM12.07.2023
NO12.10.2023
GR13.10.2023
IS12.11.2023
PT13.11.2023
Former [2024/10]AT12.07.2023
ES12.07.2023
FI12.07.2023
HR12.07.2023
LT12.07.2023
LV12.07.2023
NL12.07.2023
PL12.07.2023
RS12.07.2023
SE12.07.2023
NO12.10.2023
GR13.10.2023
IS12.11.2023
PT13.11.2023
Former [2024/09]AT12.07.2023
ES12.07.2023
FI12.07.2023
LT12.07.2023
NL12.07.2023
SE12.07.2023
NO12.10.2023
GR13.10.2023
IS12.11.2023
Former [2024/08]LT12.07.2023
NL12.07.2023
NO12.10.2023
GR13.10.2023
Former [2024/05]NL12.07.2023
Cited inInternational search[AD]WO2013125732  (TAKEDA PHARMACEUTICAL [JP]) [AD] 1-14 * the whole document *;
 [AD]WO2015073281  (LILLY CO ELI [US]) [AD] 1-14 * the whole document *;
 [A]WO2016044467  (UNIV CALIFORNIA [US]) [A] 1-14 * the whole document *;
 [A]WO2016168225  (LILLY CO ELI [US]) [A] 1-14 * the whole document *;
 [A]WO2016168222  (LILLY CO ELI [US]) [A] 1-14 * the whole document *;
 [A]  - L S Vasil"ev ET AL, "Reactions of cyanofurazans with [beta]-dicarbonyl compounds", Russian Chemical Bulletin, New York, doi:10.1023/A:1014075327382, (20010701), pages 1280 - 1286, URL: https://link.springer.com/content/pdf/10.1023/A:1014075327382.pdf, XP055562527 [A] 1-14 * compounds 8a, 8b, 8c, 10a, 10b *

DOI:   http://dx.doi.org/10.1023/A:1014075327382
by applicantWO2008101017
 WO2008152403
 WO2010070252
 WO2010070253
 WO2010070255
 WO2010070251
 WO2011006497
 WO2011160630
 WO2011160633
 WO2013092703
 WO2013125732
 WO2014041195
 WO2015073281
    - D.E. CUMMINGS et al., Diabetes, (20010000), vol. 50, no. 8, pages 1714 - 1719
    - M.R. DRUCE et al., Int. J. Obes., (20050000), vol. 29, no. 9, pages 1130 - 1136
    - W. ZHANG et al., Endocrinology, (20080000), vol. 149, no. 9, pages 4710 - 4716
    - N. WIERUP et al., Regulatory Peptides, (20020000), vol. 107, pages 63 - 69
    - R.J. KUPPENS et al., Endocrine, (20150000), vol. 50, no. 3, pages 633 - 642
    - F. BROGLIO et al., J.Clin.Endocrinol.Metab., (20040000), vol. 89, pages 3062 - 3065
    - A. DELPARIGI et al., J. Clin. Endocrinol. Metab., (20020000), vol. 87, no. 12, pages 5461 - 5464
    - R. GRANATA et al., Endocrinology, (20070000), vol. 148, no. 2, pages 512 - 529
    - R. GRANATA et al., J. Med. Chem., (20120000), vol. 55, no. 6, pages 2585 - 2596
    - Chemistry of Heterocyclic Compounds (New York, NY, United States, (19940000), vol. 30, pages 608 - 611
    - T. W. GREENE; P. G. M. WUTS, Protective Groups in Organic Synthesis, Wiley-Interscience
    - HAFFNER et al., Diabetes, (20050000), vol. 54, pages 1566 - 1572
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.